Publications by authors named "Andrew D Pearson"

Claim this Profile
P
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration.
Andrew Dj Pearson, Susan Chi, Theodore W Laetscht, Lynley Marshall, Elizabeth Raetz

Eur J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Andrew Dj Pearson, Sabine Mueller, Mariella G Filbin, Jacques Grill, Cynthia Hawkins

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
Andrew Dj Pearson, Steven G DuBois, Margaret E Macy, Teresa de Rojas, Martha Donoghue

Eur J Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed.
Claudia Rossig, Andrew D Pearson, Gilles Vassal, Nicole Scobie, Nick Bird

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Andrew Dj Pearson, Carl Allen, Jason Fangusaro, Caroline Hutter, Olaf Witt

Eur J Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Julie R Park, Judith G Villablanca, Barbara Hero, Brian H Kushner, Keith Wheatley, Andrew D Pearson

Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Andrew Dj Pearson, Nathalie Gaspar, Katherine Janeway, Quentin Campbell-Hewson, Elizabeth R Lawlor

Eur J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Andrew Dj Pearson, Claudia Rossig, Crystal Mackall, Nirali N Shah, Andre Baruchel

Eur J Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Andrew Dj Pearson, Steven G DuBois, Vickie Buenger, Mark Kieran, Kimberly Stegmaier

Eur J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Andrew Dj Pearson, Kimberly Stegmaier, Franck Bourdeaut, Gregory Reaman, Delphine Heenen

Eur J Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to address challenges and opportunities in pediatric cancer drug development?
Lucas Moreno, Steven G DuBois, Lynley V Marshall, Elizabeth Fox, Fernando Carceller, Andrew Dj Pearson

Expert Opin Drug Discov· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The challenge of defining "ultra-high-risk" neuroblastoma.
Daniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, Michael D Hogarty, John M Maris, Andrew D Pearson

Pediatr Blood Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drinking to cope moderates the efficacy of changing veteran drinking norms as a strategy for reducing drinking and alcohol-related problems among U.S. veterans.
Chelsie M Young, Eric R Pedersen, Andrew D Pearson, Clayton Neighbors

Psychol Addict Behav· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers.
Andrew Dj Pearson, Delphine Heenen, Pamela R Kearns, Anne Goeres, Lynley V Marshall

Lancet Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Julie R Park, Rochelle Bagatell, Susan L Cohn, Andrew D Pearson, Judith G Villablanca

J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.
Lucas Moreno, Hubert Caron, Birgit Geoerger, Angelika Eggert, Gudrun Schleiermacher, Andrew Dj Pearson

Expert Opin Drug Discov· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas.
Fernando Carceller, Neil P Jerome, Keiko Miyazaki, David J Collins, Matthew R Orton, Andrew D J Pearson

Pediatr Blood Cancer· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.
Mark A Applebaum, Zalman Vaksman, Sang Mee Lee, Eric A Hungate, Tara O Henderson, Andrew D Pearson

Eur J Cancer· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Lucas Moreno, Herve Rubie, Amalia Varo, Marie Cecile Le Deley, Loredana Amoroso, Andrew D J Pearson

Pediatr Blood Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.
Andrew D J Pearson, Sara M Federico, Isabelle Aerts, Darren R Hargrave, Steven G DuBois

Oncotarget· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
Fernando Carceller, Francisco J Bautista, Irene Jiménez, Raquel Hladun-Álvaro, Cécile Giraud, Andrew D J Pearson

Eur J Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.
Nermine O Basta, Gail C Halliday, Guy Makin, Jillian Birch, Richard Feltbower, Andrew Dj Pearson

Br J Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.
Daniel A Morgenstern, Wendy B London, Derek Stephens, Samuel L Volchenboum, Thorsten Simon, Andrew D J Pearson

Eur J Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.
Didier Frappaz, Sara M Federico, Andrew D J Pearson, Lia Gore, Margaret E Macy

Eur J Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of mechanism of action biology-driven early drug development for children with cancer.
Andrew D J Pearson, Ralf Herold, Raphaël Rousseau, Chris Copland, Brigid Bradley-Garelik

Eur J Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis